Literature DB >> 8467361

Characterization and ontogeny of P1-purinoceptors on rat vas deferens.

S M Hourani1, J Nicholls, B S Lee, E J Halfhide, I Kitchen.   

Abstract

1. The P1-purinoceptors which mediate the inhibition by adenosine of nerve-mediated contraction of the rat vas deferens have been investigated by use of the agonists N6-cyclopentyladenosine (CPA) and 5'-N-ethylcarboxamidoadenosine (NECA) and the A1-selective antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX). The ontogeny of the responses to adenosine and to the two co-transmitters which induce the contractions in this tissue, adenosine 5'-triphosphate (ATP) and noradrenaline (NA), have also been studied. 2. The order of potency for the adenosine agonists in inhibiting the nerve-mediated contractions was CPA = NECA > adenosine. Micromolar concentrations of DPCPX were required to antagonize the inhibition by adenosine and NECA of nerve-mediated responses, whereas the inhibitory effect of CPA was antagonized by nanomolar concentrations of the antagonist. 3. NECA and adenosine inhibited contractions induced by ATP (10 microM) or by NA (10 microM), NECA being at least ten fold more potent than adenosine, whereas CPA was inactive. Micromolar concentrations of DPCPX were required to antagonize the effect of adenosine on the contractions induced by ATP (10 microM). 4. Nerve-stimulated contractions could be observed in neonatal tissues from day 15 and increased with age, and could be inhibited by adenosine from this time, the potency of adenosine decreasing with age. Responses to ATP also appeared at day 15 and increased with age up to day 25, while responses to NA were present from day 10 (the earliest day tested) and decreased with age. 5. These results show that the rat vas deferens contains both prejunctional Al-receptors and postjunctional A2-receptors, and that adenosine acts on the latter populations to inhibit nerve-mediated contractions.The high potency of adenosine in the neonate and the parallel development of responses to ATP and to nerve-mediated contractions support suggestions that purinergic responses may be particularly important in neonatal tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8467361      PMCID: PMC1908010          DOI: 10.1111/j.1476-5381.1993.tb12873.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Presynaptic inhibitory actions of adenine nucleotides and adenosine on neurotransmission in the rat vas deferens.

Authors:  A S Clanachan; A Johns; D M Paton
Journal:  Neuroscience       Date:  1977       Impact factor: 3.590

Review 2.  Adenosine receptors and calcium: basis for proposing a third (A3) adenosine receptor.

Authors:  J A Ribeiro; A M Sebastião
Journal:  Prog Neurobiol       Date:  1986       Impact factor: 11.685

Review 3.  Role of adenine compounds in autonomic neurotransmission.

Authors:  T D White
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

Review 4.  Is there a basis for distinguishing two types of P2-purinoceptor?

Authors:  G Burnstock; C Kennedy
Journal:  Gen Pharmacol       Date:  1985

5.  Two phases of contractile response in rat isolated vas deferens and their regulation by adenosine and alpha-receptors.

Authors:  T C Major; R E Weishaar; D G Taylor
Journal:  Eur J Pharmacol       Date:  1989-08-29       Impact factor: 4.432

6.  Structure-activity relations for presynaptic inhibition of noradrenergic and cholinergic transmission by adenosine: evidence for action on A1 receptors.

Authors:  D M Paton
Journal:  J Auton Pharmacol       Date:  1981-09

7.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

Authors:  R F Bruns; G H Lu; T A Pugsley
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

8.  Characterization of P1-purinoceptors on rat duodenum and urinary bladder.

Authors:  J Nicholls; S M Hourani; I Kitchen
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

9.  Effects of alpha,beta-methylene ATP on biphasic responses of rat vas deferens.

Authors:  N Amobi; I C Smith
Journal:  Eur J Pharmacol       Date:  1987-01-06       Impact factor: 4.432

10.  Post-natal development of functional neurotransmission in rat vas deferens.

Authors:  A MacDonald; J C McGrath
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

View more
  7 in total

Review 1.  Purinergic signalling in the reproductive system in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-23       Impact factor: 3.765

2.  Selective enhancement by an adenosine A1 receptor agonist of agents inducing contraction of the rat vas deferens.

Authors:  V R Brownhill; S M Hourani; I Kitchen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

3.  The ontogenetic profiles of the pre- and postjunctional adenosine receptors in the rat vas deferens.

Authors:  J A Peachey; V R Brownhill; S M Hourani; I Kitchen
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Effects of adenine nucleosides and nucleotides on neuromuscular transmission to the prostatic stroma of the rat.

Authors:  A Preston; W A Lau; J N Pennefather; S Ventura
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  The fade of the purinergic neurogenic contraction of the guinea-pig vas deferens: analysis of possible mechanisms.

Authors:  B Driessen; I von Kügelgen; R Bültmann; D B Elrick; T C Cunnane; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

6.  Differential effects of suramin on P2-purinoceptors mediating contraction of the guinea-pig vas deferens and urinary bladder.

Authors:  S J Bailey; S M Hourani
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  The binding of 1,3-[3H]-dipropyl-8-cyclopentylxanthine to adenosine A1 receptors in rat smooth muscle preparations.

Authors:  J A Peachey; S M Hourani; I Kitchen
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.